Phase 3 trial of 13-valent pneumococcal conjugate vaccine in children with sickle cell disease previously immunized with 23-valent pneumococcal polysaccharide vaccine

Phase 3, open-label, single-arm trial of pneumococcal 13-valent conjugate vaccine in pneumococcal disease, sponsored by Wyeth. Primary endpoints: Geometric mean fold rise in serotype-specific IgG after dose 2 relative to dose 1, Serotype-specific IgG geometric mean concentrations after one versus two doses and 1 more. Started Jul 2009; status: completed.